• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

    2/10/25 4:01:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email

    - Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results.

    "During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "The company is now well positioned for growth with plans for an independent commercial launch in 2025 and the potential for multiple partner launches over the coming few years. Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025 with potential study completion in 2026. We see emerging high-value potential in our obesity and CNS programs entering early clinical studies. Arrowhead is currently funded into 2028 with further cash runway potential with multiple wholly owned candidates providing opportunities for additional partnerships."

    Selected Recent Events

    • Announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome, a severe and rare genetic disease.
      • The clinical basis of the NDA submission is comprised of the positive findings from the Phase 3 PALISADE study with supportive confirmatory evidence from the Phase 2 clinical studies of the SUMMIT program.
      • PALISADE successfully met its primary endpoint and all multiplicity-controlled key secondary endpoints, including statistically significant reductions in triglycerides, apolipoprotein C-III, and the incidence of acute pancreatitis.
      • The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting.
    • Signed and closed a licensing and collaboration agreement with Sarepta Therapeutics. Upon closing, Arrowhead receives $825 million, consisting of $500 million cash and $325 million as an equity investment priced at $27.2507, representing a 35% premium to the 30-day volume weighted average price. Arrowhead will also receive $250 million to be paid over five years. Arrowhead is also eligible to receive an additional $300 million in near-term payments, royalties on commercial sales, and approximately $10 billion in potential milestone payments.
    • Announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These data were presented in two oral presentations at the American Heart Association Scientific Sessions 2024 (AHA24) and PALISADE data was simultaneously published in the AHA journal, Circulation. Key results include the following:
      • Plozasiran induced deep and sustained reductions in triglycerides and impacted a wide spectrum of lipoproteins that may be involved with atherosclerotic cardiovascular disease.
      • Similar responses were observed in patients with genetically confirmed and clinically diagnosed familial chylomicronemia syndrome.
      • Mean reductions from baseline in triglycerides of up to -73% in patients from MUIR and -86% in patients from SHASTA-2 with favorable reductions in remnant cholesterol and non-HDL-cholesterol were observed through 15 months follow up in the open-label extension.
      • Overall, plozasiran has been generally well-tolerated to date. In the PALISADE study, the most frequently reported treatment emergent adverse events for the 25 mg dose were abdominal pain, COVID-19, nasopharyngitis, and nausea. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain.
    • Initiated a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNAi therapeutic being developed as a potential treatment for obesity.
      • ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue.
      • In preclinical studies, ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies.
    • Filed for and recently received regulatory clearance in New Zealand to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNAi therapeutic being developed as a potential treatment for obesity.
    • Presented interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNAi therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases.
      • Demonstrated near complete inhibition in hemolytic activity and functional activity of the alternative complement pathway.

    Selected Fiscal 2025 First Quarter Financial Results

    ARROWHEAD PHARMACEUTICALS, INC.

    CONSOLIDATED CONDENSED FINANCIAL INFORMATION

    (in thousands, except per share amounts)

    OPERATING SUMMARY

    Three Months December 31,

     

    2024

     

     

     

    2023

     

    (unaudited)

    Revenue

    $

    2,500

     

    $

    3,551

     

    Operating Expenses:

     

    Research and development

     

    137,002

     

     

    116,491

     

    General and administrative expenses

     

    26,910

     

     

     

    23,605

     

    Total operating expenses

     

    163,912

     

     

    140,096

     

    Operating loss

     

    (161,412

    )

     

     

    (136,545

    )

    Total other expense

     

    (13,703

    )

     

     

    (2,144

    )

    Loss before income tax expense and noncontrolling interest

     

    (175,115

    )

     

     

    (138,689

    )

    Income tax expense (benefit)

     

    103

     

     

     

    (3,313

    )

    Net loss including noncontrolling interest

     

    (175,218

    )

     

     

    (135,376

    )

    Net loss attributable to noncontrolling interest, net of tax

     

    (2,133

    )

     

    (2,512

    )

    Net loss attributable to Arrowhead Pharmaceuticals, Inc.

    $

    (173,085

    )

     

    $

    (132,864

    )

     

    Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted

    $

    (1.39

    )

     

    $

    (1.24

    )

    Weighted-average shares used in calculating - Diluted

     

    124,848

     

     

    107,415

     

     

     

    FINANCIAL POSITION SUMMARY

    December 31, 2024

    September 30, 2024

    (unaudited)

    Cash, cash equivalents and restricted cash

    $

    53,889

     

     

    $

    102,685

     

    Investments

     

    499,046

     

     

    578,276

     

    Total cash resources (cash and investments)

     

    552,935

     

     

     

    680,961

     

    Other assets

     

    460,759

     

     

    458,841

     

    Total Assets

    $

    1,013,694

     

     

    $

    1,139,802

     

     

    Liability related to the sale of future royalties

    $

    346,776

     

     

    $

    341,361

     

    Credit Facility

     

    409,414

     

     

    393,183

     

    Other liabilities

     

    201,429

     

     

     

    214,195

     

    Total Liabilities

    $

    957,619

     

    $

    948,739

     

     

    Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity

     

    52,589

     

     

     

    185,444

     

    Noncontrolling Interest

     

    3,486

     

     

    5,619

     

    Total Noncontrolling Interest and Stockholders' Equity

    $

    56,075

     

     

    $

    191,063

     

    Total Liabilities, Noncontrolling Interest and Stockholders' Equity

    $

    1,013,694

     

    $

    1,139,802

     

     

    Shares Outstanding

     

    125,572

     

     

    124,376

     

     

    Webcast and Conference Call and Details

    Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.

    For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI10095fd77113444788810d4774d5fae3. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

    About Plozasiran

    Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism. APOC3 increases triglyceride levels in the blood by inhibiting breakdown of TRLs by lipoprotein lipase and uptake of TRL remnants by hepatic receptors in the liver. The goal of treatment with plozasiran is to reduce the level of APOC3, thereby reducing triglycerides and restoring lipids to more normal levels.

    In multiple clinical studies, investigational plozasiran has demonstrated reductions in triglycerides and multiple atherogenic lipoproteins in patients with familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (SHTG), and mixed hyperlipidemia. Plozasiran has been generally well tolerated to date with treatment emergent adverse events reported that generally reflect the comorbidities and underlying conditions of the study populations. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain.

    Plozasiran is being investigated in the SUMMIT program of clinical studies, including the PALISADE Phase 3 study in patients with FCS, the SHASTA studies in patients with SHTG, and the MUIR and CAPITAN studies in patients with mixed hyperlipidemia.

    Plozasiran in the treatment of patients with FCS has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the European Medicines Agency. Investigational plozasiran has not been reviewed or approved to treat any disease.

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

    Safe Harbor Statement under the Private Securities Litigation Reform Act:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

    Source: Arrowhead Pharmaceuticals, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250210172575/en/

    Arrowhead Pharmaceuticals, Inc.

    Vince Anzalone, CFA

    626-304-3400

    [email protected]

    Investors:

    LifeSci Advisors, LLC

    Brian Ritchie

    212-915-2578

    [email protected]

    Media:

    LifeSci Communications, LLC

    Kendy Guarinoni, Ph.D.

    724-910-9389

    [email protected]

    Get the next $ARWR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARWR

    DatePrice TargetRatingAnalyst
    6/5/2024$31.00Neutral
    Goldman
    12/4/2023$29.00Buy
    BofA Securities
    9/19/2023$33.00Neutral
    Citigroup
    7/21/2023Outperform
    TD Cowen
    5/12/2023$40.00Outperform → Market Perform
    SVB Securities
    4/26/2023$80.00Outperform
    SMBC Nikko
    4/12/2023$21.00 → $35.00Market Perform → Outperform
    SVB Securities
    3/21/2023$27.00Mkt Perform
    Bernstein
    More analyst ratings

    $ARWR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Anzalone Christopher Richard sold $1,533,337 worth of shares (141,122 units at $10.87), decreasing direct ownership by 3% to 3,921,255 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      4/11/25 6:20:07 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Anzalone Christopher Richard was granted 340,000 shares and sold $774,975 worth of shares (51,425 units at $15.07), increasing direct ownership by 8% to 4,062,377 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/17/25 5:45:33 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Anzalone Christopher Richard sold $5,274,334 worth of shares (300,000 units at $17.58) and exercised 300,000 shares at a strike of $7.75 (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/5/25 6:32:06 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/20/24 7:06:58 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    SEC Filings

    See more
    • Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

      4/15/25 3:50:07 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B7 filed by Arrowhead Pharmaceuticals Inc.

      424B7 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

      3/7/25 4:15:52 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13D filed by Arrowhead Pharmaceuticals Inc.

      SCHEDULE 13D - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      2/14/25 5:23:17 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ARWR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using

      5/7/25 7:30:00 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI06c63c27dc8a4e368d2a8316c4143218. Once registered, you will

      4/30/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

      4/15/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

      SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      11/14/24 9:38:25 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.

      SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      10/16/24 9:15:20 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      4/10/24 2:03:52 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Leadership Updates

    Live Leadership Updates

    See more
    • Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

      4/15/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

      NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

      1/22/25 5:54:00 PM ET
      $APO
      $ARWR
      $B
      $GWRE
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turnstone Biologics Appoints William Waddill to its Board of Directors

      SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

      4/16/24 9:00:00 AM ET
      $ANNX
      $ARWR
      $PTGX
      $TSBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ARWR
    Financials

    Live finance-specific insights

    See more
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI06c63c27dc8a4e368d2a8316c4143218. Once registered, you will

      4/30/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

      - Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. "During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "The company is now well positioned for

      2/10/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI10095fd77113444788810d4774d5fae3. Once registered, you will

      1/22/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Arrowhead with a new price target

      Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00

      6/5/24 7:11:50 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Arrowhead with a new price target

      BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00

      12/4/23 7:19:37 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Arrowhead with a new price target

      Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00

      9/19/23 7:26:13 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care